- Home
- NEN vs ENTA Comparison
NEN vs ENTA Comparison
Compare NEN & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- ENTA
- Stock Information
- Founded
- NEN 1977
- ENTA 1995
- Country
- NEN United States
- ENTA United States
- Employees
- NEN N/A
- ENTA N/A
- Industry
- NEN Building operators
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- ENTA Health Care
- Exchange
- NEN Nasdaq
- ENTA Nasdaq
- Market Cap
- NEN 279.4M
- ENTA 245.4M
- IPO Year
- NEN N/A
- ENTA 2013
- Fundamental
- Price
- NEN $82.49
- ENTA $9.34
- Analyst Decision
- NEN
- ENTA Buy
- Analyst Count
- NEN 0
- ENTA 3
- Target Price
- NEN N/A
- ENTA $19.67
- AVG Volume (30 Days)
- NEN 394.0
- ENTA 163.5K
- Earning Date
- NEN 01-01-0001
- ENTA 11-25-2024
- Dividend Yield
- NEN 1.94%
- ENTA N/A
- EPS Growth
- NEN 67.91
- ENTA N/A
- EPS
- NEN 3.91
- ENTA N/A
- Revenue
- NEN $81,169,352.00
- ENTA $71,960,000.00
- Revenue This Year
- NEN N/A
- ENTA N/A
- Revenue Next Year
- NEN N/A
- ENTA $5.14
- P/E Ratio
- NEN $21.12
- ENTA N/A
- Revenue Growth
- NEN 10.81
- ENTA N/A
- 52 Week Low
- NEN $66.25
- ENTA $8.51
- 52 Week High
- NEN $84.00
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- NEN 56.34
- ENTA 29.51
- Support Level
- NEN $79.55
- ENTA $8.72
- Resistance Level
- NEN $82.48
- ENTA $10.89
- Average True Range (ATR)
- NEN 0.77
- ENTA 0.48
- MACD
- NEN 0.14
- ENTA -0.16
- Stochastic Oscillator
- NEN 100.00
- ENTA 19.94
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.